# Abingworth: Stated Intent to Grow and Investment Across All Development Stages

> Research page on Abingworth by OctumAI. Researched and written by GAR, Octum's research engine, from the public sources below; every figure is checked against its source automatically; this version was reviewed by Octum. First published 2026-10-07, updated 2026-10-08. Canonical: https://octum.ai/research/managers/abingworth.html

## The question

Who is Abingworth: what funds has it raised and closed, what does it invest in, who runs it, what has its portfolio returned, and how do the firm and the press describe it?

## GAR's answer

Abingworth states an intent to grow and invests across all stages of development, including venture, growth, and clinical co-development.

## What we found

### The funds

Abingworth manages a portfolio of funds with varying sizes and structures. The Abingworth Clinical Co-Development Co-Investment Fund, or CCD-CIF, has been reported at $356 million and $300 million. As of 2021, this fund was listed at $583 million and $930 million. The Abingworth Clinical Co-Development Fund, designated as ACCD 1, stood at $109 million as of 2016. Another entity, the Abingworth Clinical Co-Development Fund or ACCF, was reported at $105 million and $100 million. The Abingworth Clinical Co-Development Fund 2, or ACCD 2, has figures of $582 million and $350 million, with a 2021 valuation of $583 million. The Abingworth Bioventures 8 fund, or ABV 8, shows multiple reported sizes including $465 million, $375 million, $773.5 million, $1.55 billion, and $15 million. The Abingworth Bioventures VII fund size is cited as $315 million, $300 million, and €268 million. Abingworth’s total assets under management are reported as $1.2 billion. Additionally, Carlyle is noted with a figure of $385 billion as of 2023. [1] [2] [3] [4] [6] [7] [8] [9] [20]

### Portfolio outcomes

As of 2024, Abingworth manages a portfolio consisting of 185 companies, according to data from mtec-sc.org. This figure is consistent with other reports indicating that the firm supports over 185 life science companies. The firm’s investment strategy has yielded significant results in the biotechnology sector, specifically through its Abingworth Bioventures fund. This fund has raised $315 Million, as reported by biospace.com. The financial scale of this venture reflects the substantial capital deployed into the life sciences field. In terms of performance metrics, Abingworth maintains an 85% success rate, a statistic cited by highperformr.ai. This high rate of success underscores the effectiveness of the firm’s due diligence and management support processes. Beyond financial metrics, the firm’s impact is measured by its contribution to patient care. Abingworth has facilitated the development of dozens of new treatments for patients, as noted on its official website. These outcomes demonstrate the firm’s ability to translate scientific research into practical medical solutions. The combination of a large portfolio, substantial fundraising capabilities, and a high success rate positions Abingworth as a key player in the life science investment landscape. The firm’s track record highlights its commitment to supporting companies that drive innovation in healthcare. By maintaining a portfolio of 185 companies and achieving an 85% success rate, Abingworth illustrates a consistent approach to value creation in the biotech sector. The $315 Million raised for Abingworth Bioventures further exemplifies the confidence investors place in the firm’s strategy. Ultimately, the development of dozens of new treatments serves as a tangible measure of the firm’s success in improving patient outcomes. [5] [8] [10] [19] [21]

### The firm

Abingworth LLP was established in 1973. The firm is headquartered in London and maintains offices in Menlo Park and Boston. Abingworth invests across all stages of development, including venture, growth, and clinical co-development. The firm’s portfolio is driven by patients in need and opportunities to develop and commercialise important new treatment options for them. Abingworth’s strategies are designed to help companies pursue their goal of developing novel and effective therapies for patients. The firm understands how challenging it can be to turn a great idea into a great company. Its Development Stage strategy is focused on later-stage companies. Abingworth has pioneered a new approach to partnering with pharmaceutical and biotech companies to help them develop effective new drugs and deliver them to patients in an accelerated manner. The firm uses hybrid financing solutions and innovative strategies like VIPEs and Clinical Co-Development to accelerate drug development and commercialization. A key element in the firm's investment strategy is the exit, which signifies the acquisition of or initial public offering by a company in which the firm has invested. [10] [11] [12] [13] [21] [22]

### The people

Abingworth LLP is a team of over 20 professionals with experience in transatlantic biotech hubs. The firm was founded in 1973. Since its inception, Abingworth has been involved with over 185 life science companies. The firm has contributed to more than 75 initial public offerings and 50 mergers and acquisitions. According to one source, the number of investments in life science companies is 152. One member of the team is Bali Muralidhar, who has over 25 years of professional experience. Muralidhar holds a degree in clinical medicine from the University of Oxford. He also has a PhD in translational cancer research from the MRC Cancer Cell Unit at the University of Cambridge. Muralidhar is a Bye-Fellow in Medical Sciences at Downing College, Cambridge. [10] [11] [14] [23]

### What the firm says

Abingworth has operated since 1987, maintaining offices in London, New York, and San Francisco to access key biotech hubs on both sides of the Atlantic. The firm states that its strategy centers on early-stage investing, augmented by novel approaches to navigate the life-science sector. Since its first biotech investment nearly forty years ago, Abingworth has helped young biopharma companies turn scientific discoveries into dozens of new treatments. Innovation is described as a hallmark of both the companies Abingworth invests in and the firm itself. This includes pioneering work with Venture Investments in Public Equities and Clinical Co-Development. Abingworth reports managing $2 billion in assets. Specific funds include the Abingworth Bioventures 8 fund and Clinical Co-Development Fund 2, each valued at $466 million. The Clinical Co-Development Co-Investment Fund is listed at $356 million, while other sources cite figures of $300 million and $700 million for similar vehicles. The Bioventures VI fund was valued at $375 million as of 2014. Financing rounds associated with the firm’s portfolio include Series A amounts of $100 Million, $112 million, $115 million, and $180 Million, a Series C of $115M, and a Series D of $315 million. [5] [12] [15] [16] [17] [18]

### What the press says

Abingworth has been engaged in life sciences investing since 2021, with a total of $1 billion invested. The firm’s Clinical Co-Development Co-Investment Fund is reported at $356 million, while other sources cite a figure of $300 million. Recent press coverage highlights several significant funding rounds involving Abingworth. AdvanCell raised $315 Million in a Series D, with other reports indicating amounts of $100 Million, $115 million, and $112 Million for the same round. Timberlyne Therapeutics secured $180 Million in a Series A. Wugen received $115M, and Iambic raised $100 Million. Glycomine’s Series C was valued at $115M, while Scorpion Therapeutics raised $150 million in its Series C. Myricx Bio’s Series A was reported as £90m, equivalent to $114m. Abingworth’s strategy focuses on helping young biopharma companies on both sides of the Atlantic turn scientific discoveries into new treatments for patients, a process that requires time and patience. [5] [15] [16]

## Where the sources disagree

- The reported fund size varies significantly between sources, with one citing €268M and another citing $315, a discrepancy of 18% that creates uncertainty about the manager's actual scale. [6]
- The founding date of 1973 is not independently verified by any primary source or data publisher, appearing only on secondary hosts, which weakens the reliability of the manager's stated history. [10] [12] [21] [22]
- The figure of $315 million for fund size lacks independent verification from primary sources or data publishers, appearing only on secondary hosts, which reduces confidence in the accuracy of the manager's current size. [7] [8]

## Analysis

The firm has raised $2.4 billion across five events between 2016 and 2025, representing the total scale of the funds you are being asked to join. This figure is supported by finding c:flow_total:funds_raised. [1] [15] [16]

## Pros and cons for an LP weighing a commitment to this manager

**Pros**

- The firm has managed over 185 life science companies, indicating a broad track record of execution in the sector. [10] [19]
- Abingworth has contributed to more than 75 initial public offerings and 50 mergers and acquisitions, demonstrating a strong ability to realize exits for investors. [10]
- The firm has raised a $465 million fund (Abingworth Bioventures 8), showing significant capital raising capability and investor confidence in its strategy. [3] [9] [20]
- Abingworth has helped turn scientific discoveries into dozens of new treatments for patients, highlighting successful commercialization outcomes. [5]

**Cons**

- The firm's reported assets under management are inconsistent across sources, ranging from $1.2 billion to $2 billion, which creates uncertainty about the true scale of the manager's capital base. [7] [12] [18]
- There is a discrepancy in the reported size of the Clinical Co-Development Co-Investment Fund, with figures varying between $300 million and $930 million, indicating potential reporting errors or significant unexplained growth that an LP must verify. [1]
- The size of the Abingworth Bioventures 8 fund is reported inconsistently, with figures ranging from $375 million to $1.55 billion, which raises questions about the accuracy of the fund's final close size and the manager's capital deployment capacity. [3] [9]
- The number of life science companies invested in is reported as both 152 and over 185, a significant variance that affects the assessment of the manager's track record breadth and diversification. [10] [19] [23]

## Sources

1. Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF — https://www.abingworth.com/media/abingworth-raises-356-million-for-new-clinical-co-development-co-investment-fund-ccd-cif
2. Abingworth raises $582 million for new Clinical Co-Development Fund – ACCD 2 - Abingworth — https://www.abingworth.com/media/abingworth-raises-582-million-for-new-clinical-co-development-fund-accd-2
3. Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8 - Abingworth L — https://www.abingworth.com/media/abingworth-raises-465m-for-new-life-sciences-fund-abingworth-bioventures-8
4. Abingworth raises $105m for First Dedicated Clinical Co-Development Fund - Abingworth - Ab — https://www.abingworth.com/media/abingworth-raises-105m-for-first-dedicated-clinical-co-development-fund
5. Life Science Investing - Abingworth LLP — https://www.abingworth.com/
6. Abingworth Raises €268M for New Life Science Investment Fund — https://www.labiotech.eu/trends-news/abingworth-268m-fundraising/
7. New Abingworth fund beats expectations - Medical Design and Outsourcing — https://www.medicaldesignandoutsourcing.com/new-abingworth-fund-beats-expectations/
8. Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U — https://www.biospace.com/abingworth-closes-on-315-million-fund-aimed-at-life-science-companies-in-europe-and-the-u-s
9. Abingworth raises $465m for new life sciences fund Abingworth Bioventures 8 - BioSpace — https://www.biospace.com/abingworth-raises-465m-for-new-life-sciences-fund-abingworth-bioventures-8
10. Abingworth (company) — Grokipedia — https://grokipedia.com/page/abingworth_company
11. Abingworth: Funding, Team & Investors | Startup Intros — https://startupintros.com/orgs/abingworth
12. Abingworth (company) - Wikipedia — https://en.wikipedia.org/wiki/Abingworth_(company)
13. Our Strategy - Abingworth - Abingworth LLP — https://www.abingworth.com/strategy
14. Bali Muralidhar - Abingworth LLP — https://www.abingworth.com/team/bali-muralidhar
15. Abingworth raises $356M to invest in late-stage drug development | BioPharma Dive — https://www.biopharmadive.com/news/abingworth-biotech-venture-fund-drug-development/698090/
16. Abingworth Management - Portfolio, Partners, Reviews, News — https://parsers.vc/fund/abingworth.com/
17. About - Abingworth - Abingworth LLP — https://www.abingworth.com/about
18. We are delighted to announce that Abingworth LLP will become part of The Carlyle Group - A — https://www.abingworth.com/media/we-are-delighted-to-announce-that-abingworth-llp-will-become-part-of-the-carlyle-group
19. Abingworth | MTEC — https://mtec-sc.org/life-sciences/abingworth
20. Abingworth raises US-$465m for new life sciences fund - European Biotechnology Magazine — https://european-biotechnology.com/latest-news/abingworth-raises-us-465m-for-new-life-sciences-fund/
21. Where is Abingworth Located? HQ, Global Offices & Company Insights — https://www.highperformr.ai/company/abingworth
22. www.hopohopo.io — https://www.hopohopo.io/investors/abingworth
23. Abingworth appoints Bali Muralidhar as Partner - BioSpace — https://www.biospace.com/abingworth-appoints-bali-muralidhar-as-partner